107
ENERGOTROPIC TREATMENT OF CARDIOVASCULAR
COMPLICATIONS IN CHILDREN WITH TYPE 1 DIABETES MELLITUS
WHO HAVE SUFFERED COVID-19
Ziyaviddinova N. S. Student of II - Pediatric and medical-biological
faculty Referral pediatric case group 211
Supervisor: Associate Professor Sadirkhodjaeva A.A. Department of
Propaedeutics of Childhood Diseases, hematology TashPMI
Introduction.
Diabetes mellitus as a concomitant disease in COVID-19 is considered as one of
the significant risk factors for adverse outcomes due to a more severe course of infection in the context
of hyperglycemia and other aggravating factors in these patients, such as old age, obesity, high
frequency of concomitant pathology (hypertension, cardiovascular diseases). There are currently
virtually no verified data on the impact of different classes of sugar-lowering drugs on COVID-19
outcomes in DM. The fundamental issue of discontinuation or continuation of organoprotective therapy
remains unresolved. In the human div, carnitine acts as a regulator of lipid metabolism, facilitating the
transfer of long-chain fatty acids from the cell cytosol to the inner mitochondrial membrane, where they
are involved in the P oxidation process and become a source for the synthesis of adenosine triphosphate
- ATP. Levocarnitine as a mitochondrial fatty acid transporter limits their availability for blood
lipoprotein synthesis. Numerous clinical studies have examined the lipid-lowering effects of
levocarnitine in patients with kidney disease, diabetes mellitus, and hyperlipidemia.
Purpose of the study.
To evaluate the effectiveness of the use of energy-stimulating correction
of cardiovascular complications in type 1 diabetes mellitus in children with Covid-19.
Research materials and methods.
The paper presents an analysis of the results of observation,
laboratory methods of studies of 49 children with type 1 diabetes in children who have undergone Covid-
19, aged 4 to 18 years, the comparison group was 65 children with type 1 diabetes, the control group
was 30 practically healthy children of the same age.
Results of the study and their discussion.
According to the results of 4 weekly therapy in
patients with levocarnitine (2% solution at a dose of 200-300 mg 2 times a day) compared with the group
without levocarnitine, an increase in the concentration of anti-atherogenic HDL cholesterol was
observed (from 1,1±0,5 mmol/L to 1,29±0,5 versus 1,16±0,4 mmol/L, respectively).
After the course administration of levocarnitine, the level of triglycerides decreased slightly
(from 1,4±0,5 to 1,25±0,2 mmol/L against 1,3±0,4 mmol/L). The indicators of total cholesterol, LDL
cholesterol remained without significant changes. Metabolic disorders are the basis of the pathogenesis
of cardiovascular complications in children with DM. Levocarnitine replacement therapy adjusts energy
metabolism and is an effective method for preventing the development of DKAN in DM of Covid-19
survivors.
Conclusions
. Analyzing the data obtained, it can be concluded that metabolic changes are
indeed one of the pathogenetic mechanisms for the development of cardiovascular complications in
children with diabetes mellitus. Replacement therapy with the drug levocarnitine allows you to
adjust energy metabolism and is an effective way to prevent and reduce the development of
autonomous cardiovascular neuropathy in children with 1 DM type of Covid-19.
References:
1.
Мирзаева, У. З., С. И. Исмаилов, and Х. К. Насырова. "НАРУШЕНИЕ УГЛЕВОДНОГО
ОБМЕНА
У
ПАЦИЕНТОВ
COVID-19." BARQARORLIK
VA
YETAKCHI
TADQIQOTLAR ONLAYN ILMIY JURNALI 2.9 (2022): 117-122.
2.
Махманазарова, Л. А., Исмаилов, С. И., Алиева, А. В., & Насырова, Х. К. (2022).
СЕЗОННЫЕ ОСОБЕННОСТИ ОСТРЫХ ОСЛОЖНЕНИЙ САХАРНОГО ДИАБЕТА 1
ТИПА У ДЕТЕЙ И ПОДРОСТКОВ. Евразийский журнал медицинских и естественных
наук, 2(13), 80-86.
